# Pizarra — PT-pseudo_e001f4d06517 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e001f4d06517
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 0.21 ng/mL/yr
  - Prior PSA: 3.5 ng/mL
  - Prostate volume: 56.09 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7867544 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS 4. PSAD 0.08. Prostate volume 56 mL. csPCa 0.79.

Vitals: weight 108 kg, height 196 cm, BMI 28.1, BP 133/70 mmHg, HR 65 bpm. Smoking: Current smoker (23 pack-yr).

Chief complaint: Assessment requested for a PSA rise to 4.5 ng/mL alongside a history of a previously positive prostate biopsy.

History: At 73 years of age, this married harbour pilot, currently semi-retired, seeks clinical review due to a PSA elevation to 4.5 ng/mL. He resides independently while maintaining a close bond with his spouse and a long-standing friend who handles administrative tasks. A current smoker with a 23 pack-year history, he denies any unexplained weight loss or altered bowel habits. His daily routine includes light weight-training twice weekly, and he consumes roughly 25 units of alcohol each week. Lower urinary tract symptoms remain minimal, reflected by an IPSS score of 3. No comorbidities exist, and he takes no active medications. An earlier memory clinic screening yielded unremarkable results, and aside from occasional mild knee stiffness managed with over-the-counter analgesics, he reports feeling well. He specifically requested a morning appointment to accommodate public transit.

Physical examination: DRE: The prostate presents symmetrically enlarged, exhibiting a smooth texture and firm consistency without palpable asymmetry or discrete nodules. General inspection shows a well-nourished individual in no acute distress. Lung fields remain clear, and cardiac rhythm is regular at 65 beats per minute. Abdominal palpation yields a soft, non-tender abdomen devoid of masses or organomegaly.

Patient info: harbour pilot (semi-retired); Married; Lives alone.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 25 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 3/35 (mild LUTS).

Recent other appointments: Memory clinic — baseline screening.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.52 +/- 0.16   (95% CI 0.20-0.84)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.16  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 4.5 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current PSA rise and PI-RADS 4 finding, warrants a biopsy, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the context that the prior biopsy was positive, which fundamentally changes the interpretation of the current PI-RADS 4 finding and rising PSA. Specifically, it did not weigh the specific clinical context of a prior positive biopsy against the current findings. It also failed to integrate the specific PSA velocity (0.21 ng/mL/yr) and the specific PI-RADS 4 score into a risk stratification that accounts for prior pathology.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 52% probability, which falls into the 'discuss' tier where the model cannot distinguish between the two outcomes. This uncertainty is exacerbated by the guideline criterion stating the decision is undetermined by the panel and requires retrieved documents. A low PI-RADS score (4) against a rising PSA, combined with a prior positive biopsy, could lead to an over-biopsy if the prior positive result is not adequately contextualized against the current imaging.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value of 4.5 ng/mL?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline criterion states that the decision is undetermined by the panel and must be settled by the retrieved documents, specifically checking if the prior grade is documented or if the lesion has changed against a previous MRI.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Tergooi MC | 10 Feb 2025 | Multiparametric MRI of the Prostate
The MRI report identifies a PI-RADS 4 lesion in the right mid-gland posterior peripheral zone, measuring approximately 18 mm. This is a new finding in the context of the re-assessment, as the report is dated Feb 2025.

get_psa_trend
The serial PSA trend shows a rising trajectory: 2.7 (Feb 2024) -> 3.1 (May 2024) -> 3.5 (Aug 2024) -> 4.0 (Nov 2024) -> 4.5 (Feb 2025).

get_previous_notes
The previous notes document a prior positive biopsy from March 2024, and the patient was instructed to flag any fresh LUTS. There is no explicit documentation of the prior biopsy grade or an active surveillance protocol status in the retrieved notes.

NOT RETRIEVED
The laboratory results were deliberately left closed because the moderator's agenda did not explicitly require them, and retrieving them might introduce confounding factors (like free PSA or infection) that are not yet addressed by the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Rising PSA trend: 4.5 ng/mL in Feb 2025, following a clear upward trajectory from 2.7 ng/mL in Feb 2024.
- New/Re-assessed lesion: The MRI shows a PI-RADS 4 lesion (18 mm) in the right mid-gland posterior peripheral zone, which is the focus of the current concern.

AGAINST sampling this patient now:
- Prior positive biopsy: The prior diagnosis is established, which complicates the decision regarding re-biopsy necessity.
- Lack of prior grade: The documentation does not specify the ISUP grade or Gleason score of the prior positive biopsy.

WHERE THIS LEANS
The evidence points toward a need for further characterization due to the rising PSA and the presence of a PI-RADS 4 lesion, but the lack of prior grade documentation leaves the decision ambiguous.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents provided sufficient information regarding the rising PSA trend and the presence of a new/re-assessed PI-RADS 4 lesion, leading the evidence to lean towards biopsy despite the lack of prior grade documentation.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is driven by the rising PSA trend (from 2.7 to 4.5 ng/mL) and the presence of a new PI-RADS 4 lesion (18 mm) identified on the MRI. Although the prior positive biopsy status was noted, the lack of documentation regarding the prior ISUP grade means the current findings necessitate further characterization to guide definitive management. The statistical prior suggested biopsy, and the retrieved evidence supports this need for further tissue characterization.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
